The role of CDK4/6 inhibitors in early breast cancer.
The use of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) has proven to be a successful strategy in the treatment of advanced hormone receptor-positive (HR(+)) and human epidermal growth factor receptor 2-negative (HER2(-)) breast cancer (BC), leading to a strong interest in their possible role in...
| Autores: | , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2021 |
| País: | España |
| Institución: | Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO) |
| Repositorio: | r-FISABIO. Repositorio Institucional de Producción Científica |
| OAI Identifier: | oai:fisabio.fundanetsuite.com:p10836 |
| Acceso en línea: | https://fisabio.portalinvestigacion.com/publicaciones/10836 |
| Access Level: | acceso abierto |
| Palabra clave: | Abemaciclib Adjuvant therapy Cyclin-dependent kinase 4/6 inhibitors Early breast cancer Palbociclib |
| Sumario: | The use of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) has proven to be a successful strategy in the treatment of advanced hormone receptor-positive (HR(+)) and human epidermal growth factor receptor 2-negative (HER2(-)) breast cancer (BC), leading to a strong interest in their possible role in the treatment of early luminal BC. In this review we collect the most relevant and recent information on the use of CDK4/6i for the treatment of early BC in the neoadjuvant and adjuvant settings. Specifically, we evaluate the results of the large phase 3 adjuvant trials recently released, which have yielded apparently divergent results. We also examine the relevance of biomarkers as response predictive factors for CDI4/6i, the combination between radiotherapy and CDK4/6i, and provide a critical discussion on the evidence that we have so far and future directions of the role of these drugs in the treatment of early BC. |
|---|